Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Boehringer Ingelheim
Mallinckrodt
McKinsey

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Prexasertib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Prexasertib?

Prexasertib is an investigational drug.

There have been 17 clinical trials for Prexasertib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2018.

The most common disease conditions in clinical trials are Neoplasms, Leukemia, and Preleukemia. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).

There are eight US patents protecting this investigational drug and one hundred and fifty-five international patents.

Recent Clinical Trials for Prexasertib
TitleSponsorPhase
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and RhabdomyosarcomaMemorial Sloan Kettering Cancer CenterPhase 1/Phase 2
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsEli Lilly and CompanyPhase 1
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsSt. Jude Children's Research HospitalPhase 1

See all Prexasertib clinical trials

Clinical Trial Summary for Prexasertib

Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib

See all Prexasertib clinical trials

US Patents for Prexasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Prexasertib ⤷  Sign up for a Free Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign up for a Free Trial
Prexasertib ⤷  Sign up for a Free Trial 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN) ⤷  Sign up for a Free Trial
Prexasertib ⤷  Sign up for a Free Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Prexasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Prexasertib Australia AU2017261372 2036-05-05 ⤷  Sign up for a Free Trial
Prexasertib Canada CA3023278 2036-05-05 ⤷  Sign up for a Free Trial
Prexasertib China CN107847398 2036-05-05 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Boehringer Ingelheim
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.